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Abstract
In an attempt to further elucidate the pathomechanisms in oral squamous cell carcinoma (OSCC), gene expression
profiling was performed using a whole-transcriptome chip that contains 35,035 gene-specific 70mere oligonucleo-
tides (Human OligoSet 4.0; Operon, Cologne, Germany) to a set of 35 primary OSCCs. Altogether, 7390 genes
were found differentially expressed between OSCC tumor samples and oral mucosa. To characterize the major
biologic processes in this tumor collection, MAPPFinder, a component of GenMAPP version 2.1, was applied to
this data set to generate a statistically ranked list of molecular signaling pathways. Among others, cancer-related
pathways, such as mitogen-activated protein (MAP) kinase signaling (z score = 4.6, P< .001), transforming growth
factor-beta signaling (z score = 3.0, P = .015), and signaling pathways involved in apoptosis (z score = 2.1, P =
.037), were found deregulated in the OSCC collection analyzed. Focusing on the MAP kinase signaling pathway,
subsequent tissue microarray analyses by immunohistochemistry revealed an increase in protein expression of
MAP kinase–related proteins ERK1 in 22.8% (48 of 209) and ERK5 in 27.4% (76 of 277), respectively. An associ-
ation of high ERK5 but not of high ERK1 expression with advanced tumor stage and the presence of lymph node
metastases was found (P = .008 and P = .016, respectively). Our analysis demonstrates the reliability of the com-
bined approach of gene expression profiling, signaling pathway analyses, and tissue microarray analysis to detect
novel distinct molecular aberrations in OSCC.
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Introduction
Oral squamous cell carcinoma (OSCC) belongs to the 10 most com-
mon human malignancies worldwide, affecting more than 500,000 in-
dividuals per year. The 5-year survival rate for OSCC does not exceed
55% [1,2], which is mainly caused by locally aggressive tumor pheno-
types [3]. Furthermore, clinicopathological parameters such as the
TNM system, which are generally used as basis for therapeutic deci-
sions, frequently fail to predict the biologic behavior of the tumors or
the patients’ outcome. To improve clinical management of individual
patients, there is a strong requirement for a better understanding of
molecular events involved in OSCC pathophysiology. Attempts to
find biomarkers that identify cancerous lesions had identified several
candidate genes associated with OSCC tumor progression, including
p53, p16, MYC, CCND1, EGFR, and CCNL1 [4–7]. Up to now,
however, no single gene was shown to have sufficient diagnostic use
to predict the biologic behavior of the tumors. Although those studies
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contributed greatly to our current understanding, they did not explain
the complexity of this malignancy.
High-throughput gene expression profiling techniques offer a
unique mechanism for interrogating transcriptome-wide levels of
thousands of genes expression and have proven value in defining gene
expression signatures dividable in important subsets of patients, who
would otherwise be undetected by conventional prognostication
schemes [8,9]. Over the last few years, gene expression profiling
using microarray hybridization has provided new insights in carcino-
genesis and tumor cell dissemination. More than just focusing on the
expression of a few genes, genomic-scale expression profiles allow the
investigator to look at genetic expression variability in the context of
broader genetic themes and pathways. Likewise, the expression pro-
files of cancers may provide the identification of specific biochemical
pathways that might be targeted by new therapeutic agents.
In this study, we applied gene expression microarray technology to
a collection of 35 OSCC specimens and compared the gene expres-
sion with a pool of normal oral mucosal biopsies from healthy pa-
tients. To identify pathways, which are recurrently affected by
differential mRNA expression, the software package MAPPFinder
was used [10–12], which allows the integration and procession of
microarray data sets into the biologic context of molecular functions.
To validate individual candidate genes, which were found upregu-
lated in gene expression profiling analyses, a tissue microarray
(TMA) analysis was subsequently performed in a representative col-
lection of 306 clinically well-defined primary OSCC specimens.
Materials and Methods
RNA Expression Profiling
OSCC specimen and control samples. Thirty-five frozen tissue
tumor samples were collected from patients with histologic con-
firmed OSCC after approval by the institutional review board of
the Universitätsklinikum Heidelberg and after obtaining informed
consent. Tumor samples were cut and stained by hematoxylin-eosin.
Only samples containing at least 80% tumor cells were used for fur-
ther analyses. Six oral mucosa samples collected from healthy donors
served as control tissue. Nucleic acid extraction of high–molecular
weight RNA from frozen tumor tissue was carried out by ultracen-
trifugation as described elsewhere in detail [13].
Transcriptome amplification and labeling. Two micrograms of
total RNA from each patient and Human Universal Reference
RNA (Stratagene, La Jolla, CA) were used in a T7-polymerase–based
transcriptome amplification method, which was described elsewhere
in detail [14].
70mere oligonucleotide microarrays. A set of 35,035 gene-specific
70mere oligonucleotide probes (Human OligoSet 4.0; Operon,
Cologne, Germany) was printed on glass slides coated with epoxy–
silane (Schott Nexterion, Jena, Germany). The microarray chip rep-
resents approximately 25,100 unique genes and 39,600 transcripts
excluding control oligos. A variety of data sources was used to cover
the genes from human mitochondrial genome, RNA genes, micro-
RNA genes, the endogenous human viral genes, and the exogenous
reporter genes (Operon). Microarray production, prehybridization
treatment, hybridization, and posthybridization washes, and data ac-
quisition were performed as described previously [15]. After hybridiza-
tion and stringent washing, fluorescence intensity images were
acquired using a dual-laser scanner (G2505 B; Agilent Technologies,
Santa Clara, CA) and were analyzed with the GenePix Pro 6.0 imaging
software (Molecular Devices, Union City, CA). All hybridization ex-
periments were repeated with inversely labeled sample and reference.
Data preprocessing. Result files containing all relevant raw data
were processed using the in-house–developed ChipYard microarray
analysis software (http://www.dkfz.de/genetics/ChipYard/), the statis-
tical programming language R, and packages of the Bioconductor
project. Raw fluorescence intensity values were normalized applying
variance stabilization. We assessed the quality of all hybridizations by
generating scatter plots and gradient plots using the Bioconductor
package “limma” (www.bioconductor.org). The raw and normalized
data are deposited in the Gene Expression Omnibus database (http://
www.ncbi.nlm.nih.gov/geo/; Accession No. GSE10121).
Statistical analysis. After normalization, all gene expression data
were analyzed for differences between normal and tumor samples
using analysis of variance with Bonferroni multiple testing correc-
tion. All genes with a log-value between −1 and 1 were excluded from
further analyses. To identify pathways, which were likely to be af-
fected by differentially expression, MAPPFinder, a component of Gen-
MAPP software package version 2.1, was used [10–12]. MAPPFinder
produces a statistically ranked list of Gene Ontology (GO) biologic
categories associated with each cluster, from which the most signifi-
cant nonsynonymous groups are listed. MAPPFinder analysis was
performed on a set of 96 MAPPs, a representation of a biologic re-
lationship between genes or gene products, calculating the percentage
of genes meeting the criterion for each MAPP. A positive z score in-
dicates that there are more genes meeting the criterion in a MAPP
than would be expected by random chance. A negative z score indi-
cates that there are fewer genes meeting the criterion than would be
expected by random chance.
Quantitative real-time reverse transcriptase–polymerase chain
reaction. To validate expression profiling data, mRNA levels of se-
lected candidate genes TRIO, TNFRSF18, EGFR, MAPK3, and
MAPK7 were tested by quantitative real-time reverse transcriptase–
polymerase chain reaction (RT-PCR). For normalization purposes,
mean cDNA expression levels of the housekeeping genes PGK1
and LamininB1 were measured. Details of the experimental setup
are described elsewhere [16,17]. Primer sequences used in these ex-
periments are listed in Table W1.
Tissue Microarray Analysis
Tumor material and patients’ characteristics. Paraffin-embedded
tumor specimen of primary OSCC were obtained from the archives
of the Institute of Pathology of the University Hospital Heidelberg
after approval by the local institutional review board. For all tumor
samples, clinical and follow-up data of the patients were available
from the Department of Oral and Craniomaxillofacial Surgery of
the University Hospital Heidelberg. Mean age of the patients was
61 years at the time of diagnosis. Tumors were staged according to
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the TNM system of the International Union against Cancer (UICC).
Of 306 tumor specimens available for TMA experiments, 143 tumors
were T1/2 and 163 were T3/4 tumors. One hundred twenty-five
tumors were graded according to UICC stage I to III and 207 were
graded according to stage IV, respectively. One hundred twenty-three
tumors presented no regional lymph node metastases at the time of
diagnosis, whereas 183 exhibited regional lymph node metastases.
Tissue microarray generation. The OSCC-TMA was generated as
previously described [18]. Briefly, hematoxylin-eosin–stained sections
were cut from each donor block to define representative tumor re-
gions. Small tissue cylinders with a diameter of 0.6 mm were taken
from selected areas of each donor block using a tissue chip micro-
arrayer (Beecher Instruments, Silver Spring, MD) and were trans-
ferred to a recipient paraffin block. The recipient paraffin block was
cut in 5-μm paraffin sections using standard techniques. Five oral mu-
cosa biopsies from healthy donors were incorporated in the recipient
block as control specimen.
Immunohistochemistry. The immunohistochemistry (IHC) was
performed using the DAKO Real Kit (DAKO; Hamburg, Germany)
according to the manufacturer’s protocol. Monoclonal mouse anti-
bodies against the phosphorylated forms of ERK1 and ERK5 (Cell Sig-
naling Technology, Beverly, MA) were used at a dilution of 1:1000
for IHC experiments. The primary antibody for phosphorylated
ERK1 was the rabbit monoclonal phosphor–p44/42 mitogen-activated
protein (MAP) kinase (Thr202/Tyr204) antibody that detects endog-
enous levels of human p42 and p44 MAP kinase (ERK1 and ERK2)
only when they are phosphorylated at Thr202 and Tyr204, respectively.
The primary antibody for phosphorylated ERK5 was rabbit phospho-
Erk5 (Thr218/Tyr220) antibody that detects endogenous levels of hu-
man ERK5 MAP kinase only when they are phosphorylated at Thr218
and Tyr220, respectively. Evaluation of IHC experiments was based on
the percentage of cells, which showed distinct nuclear and cytoplasmic
staining. Oral mucosa control specimen showed slight nuclear and cy-
toplasmic staining, which was set as baseline immunoreactivity (0/
None) in the following arbitrary score: none, <5% cytoplasmic and nu-
clear staining; weak, 5% to 30% cytoplasmic and nuclear staining;
moderate, 31% to 60% cytoplasmic and nuclear staining; and strong,
>60% cytoplasmic and nuclear staining. For statistical analyses, none
and weak stainings were combined and counted as low expression,
whereas moderate and strong stainings were grouped together and
scored as high expression.
Statistical analysis. Nonparametric univariate analysis using chi-
square test was performed to compare the prevalence of high
ERK1 and ERK5 expression with T-stadium, UICC stage, and the
presence of lymph node metastases of the primary tumors. For overall
survival, Kaplan–Meier curves of tumors with high versus low ERK1
and ERK5 expression were analyzed by log-rank test. P ≤ .05 was
considered significant. All statistical analyses were performed using
R for windows version 2.4.1.
Results
70mere Microarray Expression Profiling
In the present study, n = 35 tumor specimens of primary OSCCs
were analyzed for global gene expression using 70mere oligo-
nucleotide microarrays containing 35,035 gene-specific 70mere
oligonucleotides. After quality control, an analysis of variance and
a following Bonferroni multitest were performed for the identi-
fication of differential gene expression between normal tissue and
tumor samples. Gene expression was considered as significantly
changed, if exceeding the multiple testing cutoff, computed in this
case with −log10(P) of 5.65 according to the Bonferroni criterion.
Using this approach, we identified 7390 genes significantly and dif-
ferentially expressed between OSCC and normal oral mucosa
(Table W2).
Pathway Analysis
To obtain a comprehensive view of global gene expression in
OSCC, pathway analysis was applied to this data set of 7390 genes
to identify molecular pathways that contained a number of altered
transcript levels in OSCC compared to healthy mucosa. MAPPFinder,
a component of the software package GenMAPP version 2.1 contain-
ing 96 MAPPs, was used. We ran the MAPPFinder analysis on this
data set using two criteria, either an increase (fold change > 1 and
−log10(P) > 5.65) or a decrease (fold change < −1 and −log10(P) >
5.65) in gene expression to obtain pathways with mostly upregulated
genes and pathways with mostly downregulated genes. A pathway
was defined as significantly affected by differentially expressed genes,
if P ≤ .05.
In this respect, several significantly altered pathways were revealed
with this approach. We found an amount of twenty-three deregu-
lated pathways with MAPPFinder (Table 1). Of those pathways,
which were upregulated in the tumor samples analyzed, several were
related to inflammatory response system [B cell receptor, P < .001;
interleukin (IL) 5, P < .001; IL-7, P < .001; IL-2, P < .001; tumor
necrosis factor alpha (TNFα)–nuclear factor kappa B (NF-κB), P <
.001; IL-6, P = .004; IL-4, P = .019; T cell receptor, P = .035]. Other
pathways with a high number of differentially expressed genes were
cancer-related like MAP kinase signaling (P < .001; Figure 1), trans-
forming growth factor-beta (TGF-β) signaling (P = .015), and signal-
ing pathways involved in apoptosis (P = .037). Pathways with
significantly downregulated genes were the ribosomal protein path-
way (P < .001) and the pathway of members of the electron transport
chain (P < .001). The MAP kinase signaling pathway exhibited the
highest number of altered genes. The altered expressed genes of this
pathway are listed in Table 2.
Quantitative Real-Time RT-PCR
To confirm the findings of the microarray analysis, we performed
quantitative real-time RT-PCR using primers specific for TRIO,
TNFRSF18, EGFR, MAPK3/ERK1, and MAPK7/ERK5. The fold
differences in expression between tumor specimen and control mu-
cosa specimen predicted by 70mere microarray expression profiling
were compared to those fold differences obtained by RT-PCR (see
Figure W1).
Quantitative PCR confirmed the direction of fold change in 62
(84.9%) of 73 analyses. Overall, these results confirm our findings
of differential gene expression by microarray analysis.
Tissue Microarray Analyses
From those pathways found deregulated by cDNA microarray ex-
pression profiling in the OSCC tumor samples, further analyses were
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focused on the MAP kinase signaling pathway, because MAP kinase
signaling is supposed to be critically involved in a variety of cancer-
specific functions, such as proliferation, dedifferentiation, and eva-
sion from apoptosis. For TMA analysis, antibodies against ERK1
and ERK5, which play a central role in signal transduction in the
MAP kinase signaling pathway, were selected. To test whether OSCC
also show an increase of ERK1 and ERK5 protein expression, an im-
munohistochemical analysis was performed on TMA sections (Fig-
ure 2). To assess the functional properties of these proteins in the
primary tumor tissue, antibodies against the active phosphorylated
form of ERK1 and ERK5 were used. The overall frequency of high
pERK5 expression was 27.4% (79 of 277). There was a significantly
higher prevalence for high pERK5 expression in T1/2 versus T3/4
tumors (P = .015), in Stage I to III versus Stage IV tumors (P = .008),
Table 1. Identification of Molecular Pathways with Significantly Upregulated (Above) and Downregulated Genes (Below) in OSCC Compared to Healthy Mucosa By MAPPFinder Analysis.
MAPP Name n (Changed) n (Measured) n (on MAPP) % (Changed) % (Present) z P
MAPK signaling pathway_ 72 151 162 47.7 93.2 4.675 0
TNFα–NF-κB 80 181 187 44.2 96.8 4.096 0
IL-2 NetPath 14 38 75 76 50.7 98.7 3.817 0
IL-7 NetPath 19 25 44 44 56.8 100.0 3.799 0
IL-5 NetPath 17 34 66 69 51.5 95.7 3.726 0
B cell receptor NetPath 12 68 155 158 43.9 98.1 3.681 0
GPCRDB_Other 11 83 119 13.3 69.7 −3.484 0
GPCRDB class rhodopsin-like 27 212 262 12.7 80.9 −5.873 0
Insulin signaling 65 155 159 41.9 97.5 3.144 .002
IL-6 NetPath 18 42 96 100 43.8 96.0 2.839 .004
p38 MAPK signaling pathway 17 32 34 53.1 94.1 2.777 .006
IL-3 NetPath 15 43 99 101 43.4 98.0 2.816 .007
TGF-β receptor 57 145 151 39.3 96.0 2.331 .015
Proteasome degradation 23 50 61 46.0 82.0 2.38 .017
IL-4 NetPath 16 27 62 62 43.5 100.0 2.233 .019
Peptide GPCRs 10 60 73 16.7 82.2 −2.37 .026
IL-9 NetPath 20 12 23 24 52.2 95.8 2.252 .032
T cell receptor NetPath 11 50 129 135 38.8 95.6 2.053 .035
mRNA processing reactome 48 121 127 39.7 95.3 2.207 .036
Apoptosis 33 80 82 41.3 97.6 2.092 .037
Fas pathway and stress induction 17 36 38 47.2 94.7 2.175 .041
Fatty acid beta oxidation 3 5 8 8 62.5 100.0 1.959 .046
Ribosomal_Proteins 35 84 88 41.7 95.5 15.668 0
Electron transport chain 21 103 105 20.4 98.1 7.309 0
Figure 1. Overview of differentially expressed genes in 35 OSCC compared to six healthy mucosa specimen involved in MAP kinase
signaling (modified from the KEGG MAPK pathway). Dark gray color of gene symbols represents the significance of difference [−log10
(P)]; the corresponding numbers are the average fold change (log fold).
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and for tumors with lymph node metastasis (N1–3) versus tumors with-
out lymph node metastasis (N0, P = .016). For high pERK1 expression,
the overall frequency was 22.8% (48 of 209) without obtaining any cor-
relation of high pERK1 expression with the clinical parameters ana-
lyzed. All data obtained from TMA analyses are shown in Table 3.
Kaplan–Meier analysis revealed no difference in the overall survival
for tumors with high expression versus low/no expression of the pro-
teins analyzed (P > .05, data not shown).
Discussion
Gene expression profiling to OSCC specimen using different types
of cDNA arrays has been performed in several studies to define dis-
tinct expression signatures for specific clinical stages [19,20]. To ac-
tually understand the process of OSCC progression and metastases,
however, it would be essential to know which biologic aberrations are
represented by these classifying genes and to what extent they con-
tribute to tumorigenesis. To obtain a comprehensive overview of ac-
tivated signal transduction pathways in biologic systems, several
programs have been developed, which allow the integration and pro-
cession of microarray data sets into the context of molecular func-
tions and interrelated dependencies of annotated genes [21–23]. In
contrast to those approaches, however, which mainly focus on well-
defined metabolic pathways, the program MAPPFinder, which was
used in the present analysis, is closely linked to a broader base of
pathway information provided by the GO Consortium [11,12].
MAPPFinder dynamically links gene expression data to the GO hi-
erarchy at the level of biologic processes, thereby making it a valuable
tool to define novel aberrant pathways in homogenous cohorts of
tumor samples [24].
In the present study, a whole-transcriptome expression analysis was
performed for 35 OSCC specimens resulting in 7390 differentially
expressed transcripts compared to a pool of healthy mucosa samples.
By subsequent pathway analysis using MAPPFinder, 24 aberrantly
expressed molecular pathways were detected. Among the cancer-
related pathways in this data set, most distinct aberrations—mostly
upregulations—were found in the MAP kinase signaling network.
The MAP kinase signaling pathways are involved in various cellular
functions, including cell proliferation, differentiation, and migration
by the activation of protooncogenes such as JUN, FOS, MYC, and
ELK1 (Figure 1). Four MAP kinase signaling pathways have been iden-
tified, namely, the ERK1 pathway, the c-jun N-terminal–regulated ki-
nase (JNK) pathway, the p38 pathway, and the ERK5 pathway [25].
Whereas the JNK and the p38 pathway are signaling cascades, which
are mainly stress-activated by proinflammatory cytokines, ERK1 and
ERK5 are additionally induced by epidermal growth factor receptor
(EGFR) activation [26]. Because EGFR activation is known to be de-
cisively involved in head and neck squamous cell carcinoma (HNSCC)
initiation and progression [27], subsequent analyses were focused on
ERK1 and ERK5 signaling pathways in the present study. High
ERK1 expression and an association with tumor progression and ad-
verse clinical outcome had been observed in several tumor entities, e.g.
in primary hepatocellular carcinoma [28], cholangiocarcinoma [29],
breast cancer [30], and non–small cell lung cancer [31]. For HNSCC,
an involvement of ERK1 signaling in angiogenic processes through
vascular endothelial growth factor activation was postulated [32]. In
our present TMA analysis, high ERK1 protein expression was found
in about 20% of primary OSCC tumor samples. Surprisingly, however,
an association with clinical parameters such as advanced UICC stage
and presence of lymph node metastases was not found for high ERK1
but for high ERK5 protein expression, although ERK1 and ERK5 co-
expression was frequently found. Mitogen signal–regulated ERK5
overexpression was shown to be associated with metastatic prostate
cancer [33], but for HNSCC or OSCC, a participation of ERK5 ex-
pression in tumor progression has not yet been described. Analyses of
tumor cell systems, however, suggested that MAP kinase signaling
through ERK5 is a distinct molecular pathway, which might regulate
cellular functions such as the activation of protooncogenes originally
attributed to ERK1 [34]. Furthermore, it could be shown that
ERK5 but not ERK1 signaling contributes to Src-mediated disruption
of actin cytoskeleton organization [35]. Because the disorganization of
the cytoskeleton is known to be one of the initial steps that are re-
quired for the development of metastases, this observation is in con-
cordance with our data of a correlation of high ERK5 expression and
the presence of lymph node metastases in OSCC. Therefore, one
might speculate that ERK5 signaling is more important in the
EGFR-mediated metastasizing process in OSCC than in the classic
ERK1 signaling pathway.
A further distinct finding in signaling pathway analysis of the ex-
pression profiling data obtained from the OSCC collection was fre-
quently upregulated pathways involved in inflammatory response,
e.g., B cell receptor signaling, TNFα signaling, IL-2 signaling, IL-5
signaling, and T cell receptor signaling (Table 1). In general, it is a
well-investigated phenomenon that inflammation plays an important
role in tumor promotion, particularly in HNSCC development [36].
It was recently postulated that tumor cells can modify the surround-
ing stroma through the production of cytokines and growth factors
and that this locally changed host microenvironment influences the
proliferative and invasive behavior of tumor cells [37]. Particularly for
HNSCC, it has been demonstrated that primary tumors express a
variety of proinflammatory cytokines, including IL-1a, IL-6, IL-8,
and granulocyte macrophage colony–stimulating factor that may at-
tract immune effector cells to the tumor microenvironment [38]. In
this context, one might interpret the results of the pathway analysis,
which showed an increased expression of proinflammatory molecules
in the tumor biopsies, as a distinct tumor-specific feature involved in
the pathogenesis of the infiltrating process. Conversely, however, in-
flammatory cytokines are also expressed by cells of the immune sys-
tem themselves during such an inflammatory process. Therefore, the
inflammatory cell infiltration at the invasion front of the tumor
might be the source of high cytokine expression as well. Although
only tumor samples containing at least 80% tumor cell load in the
biopsy were used for expression profiling analysis in the present
study, a contamination with cells of the immune system cannot be
definitely excluded. Nevertheless, with the development of more ef-
ficient microdissection techniques and RNA amplification protocols,
a whole-transcriptome expression profiling with smaller RNA sam-
ples would be possible. Then, a comprehensive signaling pathway
analysis of the expression of immunomodulatory molecules might
be a promising approach to further define the role of inflammation
in OSCC progression.
Furthermore, pathway analyses showed a significant upregulation of
apoptosis-related genes. Although evading apoptosis is a hallmark of
almost all malignant tumors, little is known about the actual role
of apoptosis-related genes in OSCC development. Previous analyses,
for example, suggested increased levels of the anti-apoptotic protein
bcl-2 in OSCC samples [39–41]. A recent study, however, using an
animal model system exhibiting chemically induced OSCC, found a
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Table 2. Increased Expression of Genes Involved in MAP-Kinase Signaling Pathway in 35 OSCC Samples Compared to Six Healthy Mucosa Specimens.
Ensembl ID Gene Symbol Gene Name −log10(P) log (Fold Change)
ENSG00000100311 PDGFB Platelet-derived growth factor B chain precursor 15.467 3.05696878
ENSG00000180370 PAK2 Serine/threonine–protein kinase PAK 2 14.294 3.807238826
ENSG00000107566 CHUK SPFH domain-containing protein 1 precursor 14.274 4.832758228
ENSG00000114738 MAPKAPK3 MAP kinase–activated protein kinase 3 14.104 4.067114259
ENSG00000089022 MAPKAPK5 MAP kinase–activated protein kinase 5 12.030 2.129482743
ENSG00000137764 MAP2K5 Dual-specificity mitogen–activated protein kinase kinase 5 11.859 4.950684923
ENSG00000105221 AKT2 RAC-beta serine/threonine–protein kinase 11.838 5.375739428
ENSG00000154229 PRKCA Protein kinase C alpha type 11.549 2.137398935
ENSG00000119699 TGFB3 Transforming growth factor beta-3 precursor 11.317 5.585986774
ENSG00000166484 MAPK7 Mitogen-activated protein kinase 7 11.211 2.721242004
ENSG00000105550 FGF21 Fibroblast growth factor 21 precursor (FGF-21) 11.099 1.828757871
ENSG00000167193 CRK Protooncogene C-crk 10.696 4.945734007
ENSG00000142208 AKT1 RAC-alpha serine/threonine–protein 10.577 4.734240647
ENSG00000108861 DUSP3 Dual-specificity protein phosphatase 3 10.476 3.187181556
ENSG00000115953 PPP3R1 Calcineurin subunit B isoform 1 10.403 1.687353652
ENSG00000156711 MAPK13 Mitogen-activated protein kinase 13 9.925 3.877349348
ENSG00000085276 EVI1 Ecotropic virus integration 1 site protein 9.862 1.102867786
ENSG00000099725 PRKY Serine/threonine–protein kinase PRKY 9.857 4.186894009
ENSG00000126458 RRAS Ras-related protein R-Ras 9.828 3.738753854
ENSG00000142733 MAP3K6 Mitogen-activated protein kinase kinase kinase 6 9.684 4.164230763
ENSG00000112658 SRF Serum response factor 9.667 2.390663287
ENSG00000169032 MAP2K1 Dual-specificity mitogen-activated protein kinase kinase 1 9.664 4.265539167
ENSG00000112062 MAPK14 Mitogen-activated protein kinase 14 9.647 1.394125597
ENSG00000138794 CASP6 Caspase-6 precursor 9.462 2.734601578
ENSG00000149269 PAK1 Serine/threonine–protein kinase PAK 1 9.420 2.504398448
ENSG00000106799 TGFBR1 TGF-beta receptor type I precursor 9.414 2.058273508
ENSG00000174775 HRAS GTPase HRas precursor 9.398 5.345430439
ENSG00000104365 IKBKB Inhibitor of nuclear factor kappa B kinase beta subunit 9.303 2.735869467
ENSG00000162889 MAPKAPK2 MAP kinase–activated protein kinase 2 9.128 3.689152094
ENSG00000109971 HSPA8 Heat shock cognate 71 kDa protein 9.061 4.628190782
ENSG00000077782 FGFR1 Basic fibroblast growth factor receptor 1 precursor 9.035 4.913382054
ENSG00000075429 CACNG5 Voltage-dependent calcium channel gamma-5 subunit 8.976 −1.9493298
ENSG00000127191 TRAF2 TNF receptor–associated factor 2 8.954 2.247565686
ENSG00000113013 HSPA9B Stress-70 protein, mitochondrial precursor 8.893 5.378858628
ENSG00000177885 GRB2 Growth factor receptor–bound protein 2 8.777 3.249343399
ENSG00000132155 RAF1 RAF protooncogene serine/threonine–protein kinase 8.731 4.607548955
ENSG00000011485 PPP5C Serine/threonine–protein phosphatase 5 8.703 2.290087262
ENSG00000071054 MAP4K4 Mitogen-activated protein kinase kinase kinase kinase 4 8.438 4.156174225
ENSG00000161326 DUSP14 Dual-specificity protein phosphatase 14 8.327 4.528707616
ENSG00000067191 CACNB1 Voltage-dependent L-type calcium channel beta-1 subunit 7.982 1.761273845
ENSG00000107643 MAPK8 Mitogen-activated protein kinase 8 7.942 1.56455685
ENSG00000106211 HSPB1 Heat shock protein beta-1 (HspB1) 7.838 1.440732073
ENSG00000126934 MAP2K2 Dual-specificity mitogen-activated protein kinase kinase 2 7.818 2.378935599
ENSG00000140285 FGF7 Fibroblast growth factor 7 precursor (FGF-7) 7.738 −1.472920826
ENSG00000120875 DUSP4 Dual-specificity protein phosphatase 4 7.623 2.488597455
ENSG00000105329 TGFB1 Transforming growth factor beta-1 precursor 7.621 3.393246251
ENSG00000134259 NGFB Beta-nerve growth factor precursor (Beta-NGF) 7.586 1.28841258
ENSG00000075388 FGF4 Fibroblast growth factor 4 precursor (FGF-4) 7.549 4.415819419
ENSG00000128272 ATF4 Cyclic AMP–dependent transcription factor ATF-4 7.490 4.632776685
ENSG00000126583 PRKCG Protein kinase C gamma type 7.399 2.201198322
ENSG00000166501 PRKCB1 Protein kinase C beta type 7.396 2.359630993
ENSG00000132906 CASP9 Caspase-9 precursor 7.367 4.394431415
ENSG00000100485 SOS2 Son of sevenless homolog 2 7.271 2.816563747
ENSG00000128340 RAC2 Ras-related C3 Botulinum toxin substrate 2 precursor 7.256 1.929198943
ENSG00000107968 MAP3K8 Mitogen-activated protein kinase kinase kinase 8 7.202 2.884100613
ENSG00000138834 MAPK8IP3 C-jun–amino-terminal kinase-interacting protein 3 7.163 2.707867082
ENSG00000123739 PLA2G12A Group XIIA secretory phospholipase A2 precursor 7.105 −1.889796803
ENSG00000143851 PTPN7 Tyrosine-protein phosphatase nonreceptor type 7 6.948 1.921973144
ENSG00000102882 MAPK3 Mitogen-activated protein kinase 3 6.906 3.478604152
ENSG00000176697 BDNF Brain-derived neurotrophic factor precursor (BDNF) 6.825 1.762730087
ENSG00000141480 ARRB2 Beta-arrestin-2 (Arrestin, beta 2) 6.756 2.512394619
ENSG00000085511 MAP3K4 Mitogen-activated protein kinase kinase kinase 4 6.655 1.171686631
ENSG00000186895 FGF3 Fibroblast growth factor 3 precursor (FGF-3) 6.651 1.401698475
ENSG00000115904 SOS1 Son of sevenless homolog 1 6.630 2.41943162
ENSG00000141510 TP53 Tumor suppressor p53-binding protein 1 6.479 2.802984167
ENSG00000073009 IKBKG NF-κB essential modulator (NEMO) 6.358 2.203573687
ENSG00000170458 CD14 Monocyte differentiation antigen CD14 precursor 6.330 3.763791737
ENSG00000155903 RASA2 Ras GTPase-activating protein 2 6.092 1.297339857
ENSG00000136238 RAC1 Ras-related C3 Botulinum toxin substrate 1 precursor 6.078 −2.009429284
ENSG00000120129 DUSP1 Dual-specificity protein phosphatase 1 6.043 2.637357306
ENSG00000138032 PPM1B Protein phosphatase 2C isoform beta 6.006 3.908525816
ENSG00000058335 RASGRF1 Guanine nucleotide–releasing protein 5.905 2.008095195
ENSG00000134853 PDGFRA Alpha platelet–derived growth factor receptor precursor 5.808 1.093708029
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high expression of the proapoptotic protein bax but decreased levels
of bcl-2 in early oral cancer specimens [39]. Another study on ad-
vanced primary OSCC showed an association of high expression of
the antiapoptotic protein survivin, with favorable outcome of the pa-
tients [42]. Tissue microarray technology might be helpful to further
delineate the precise role of apoptosis-related genes in OSCC initia-
tion and progression.
Whereas most of the aberrant signaling pathways were identified
as upregulated, the expression of ribosomal proteins was found as
significantly downregulated in the tumor collection analyzed. Fur-
thermore, MAPPFinder analysis defined the highest z value for ribo-
somal protein signaling of all pathways analyzed, indicating that its
downregulation might be a decisive aberration in OSCC specimen
compared to oral mucosa specimen. Only a few published studies have
evaluated the role of cytoplasmic ribosomal proteins in carcinogenesis.
Significant changes in the expression of several ribosomal proteins have
been reported to occur in colorectal carcinoma [43]. In ovarian tumor
cell lines, ribosomal proteins, such as S8, S24, and L32, are much
more abundantly expressed in differentiated tumor cells than in less-
differentiated ones [44]. For OSCC, a downregulation of some ribo-
somal proteins were found in a previous cDNA expression profiling
study, with the downregulation of ribosomal protein S13 discrimi-
nating between metastatic and nonmetastatic OSCC in small tumor
collection [45]. Because of the observation that a large number of
genes encoding ribosomal protein are downregulated in OSCC in
our study, further detailed investigation to prove the significance of
such global downregulation is warranted.
Pathway signaling analyses results not only contribute to a better
understanding of molecular and cellular functions and the definition
of potential biomarkers but also open the gate to novel molecular
Table 2. (continued )
Ensembl ID Gene Symbol Gene Name −log10(P) log (Fold Change)
ENSG00000113578 FGF1 Fibroblast growth factor 1 precursor (FGF-1) 5.786 2.292817534
ENSG00000135090 TAOK3 Serine/threonine–protein kinase TAO3 5.759 2.493439143
ENSG00000072062 PRKACA cAMP-dependent protein kinase, alpha-catalytic subunit 5.661 1.435441441
ENSG00000104814 MAP4K1 Mitogen-activated protein kinase kinase kinase kinase 1 5.626 2.539747316
ENSG00000142875 PRKACB cAMP-dependent protein kinase, beta-catalytic subunit 5.604 2.081661093
For each transcript, the mean value of these six mucosa specimens was subtracted. An increased expression was defined if this value was higher than three standard deviations of these six healthy mucosa specimens.
Figure 2. Detection of differential pERK1 (left side) and pERK5 (right side) protein expression on TMA sections as detected by IHC.
Normal oral mucosa specimens (A and D; original magnification, ×20) exhibit a slight pERK1 and pERK5 staining. For OSCC specimen,
two examples of absent (B and E; original magnification, ×20) and high (C and F; original magnification, ×20) ERK1 and ERK5 protein
expression are shown.
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targets for specific therapeutic approaches. For ERK1, the negative
effect on cell proliferation using specific ERK1 inhibitors has been
shown in several tumor systems. In metastasizing neuroblastoma,
ERK1 inhibition by the bisphosphonate zoledronic results in a de-
crease in tumor cell proliferation and an increase in tumor cell apopto-
sis [46]. For papillary thyroid carcinoma carrying an ERK1-activating
BRAF mutation, specific ERK1 inhibition resulted in tumor cell
growth arrest [47]. Similar effects of tumor cell growth inhibition after
blocking ERK1-mediated signaling were found in cholangiocarcinoma
[48] and hepatocellular carcinoma [49]. For HNSCC, targeted therapy
has been recently established in clinical management by the use of the
monoclonal antibody cetuximab that selectively inhibits EGFR. Al-
though cetuximab has proven antitumor activity as a single agent
and in combination with radio- and chemotherapy [50], a significant
number of patients do not adequately respond to cetuximab treatment.
Therefore, it has been postulated that a combination therapy with the
additional specific inhibition of downstream mediators of EGFR sig-
naling might be a useful approach to increase cetuximab response
[27,51]. In this context, according to the data from the present study,
ERK5, as a downstream mediator of EGFR, which is associated with
advanced tumor stage, might be a novel molecular target. The use of
specific ERK5 inhibitors to block EGFR-induced tumor cell prolifer-
ation might be a promising approach to support antitumor activity of
cetuximab in HNSCC treatment.
In conclusion, the combined experimental approach of whole-
transcriptome expression profiling, automated signaling pathway
analysis and protein expression analyses by tissue microarrays resulted
in the rapid definition of molecular components, which are critically
involved in tumor progression. It allowed the evaluation of diag-
nostic and prognostic biomarkers as well as the definition of novel
promising therapeutic targets. ERK5-mediated signaling of EGFR
activation might be more important for OSCC progression than
ERK1-mediated signaling, suggesting ERK5 as a potential interfer-
ence point in future therapeutic approaches.
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Table W1. List of RT-PCR Primer to Validate Expression Profiling Data.
Gene Forward Primer Reverse Primer
MAPK3 5′-GCT ACA CGC AGT TGC AGT AC-3′ 5′-CAG TAG GTC TGA TGT TCG AAG-3′
MAPK7 5′-ACA TCA TCG CCA TCA AGG ACA T-3′ 5′-AGG AAG TAG CGC ACG TGT TC-3′
MAPK8 5′-CTG TGT GGA ATC AAG CAC CTT CA-3′ 5′-GTG CTC TGT AGT AGC GAG TCA CT-3′
MAPK9 5′-ATT CAC ATG GAG CTG GAT CAT GA-3′ 5′-CCA GGC CAA AGT CAA GGA TCT TC-3′
Trio 5′-CCT CAG AGC TGC AGG ACC TAG-3′ 5′-C51CGA CTT CCC ATC TTG GCT GAC-3′
SDF4 5′-CAC GTG TCT TGG GAC GAG TA-3′ 5′-CAG GTT CTC CAG GAC TTC CT-3′
FGF3 5′-GTA CCT GGC CAT GAA CAA GAG-3′ 5′-CAT ACG TAT TAT AGC CCA GCT CG-3′
EGF 5′-CAC GAT GGG TAC TGC CTC CAT G-3′ 5′-GCG CAG TTC CCA CCA CTT-3′
EGFR 5′-CCA CCA CGT ACC AGA TGG ATG T-3′ 5′-ACG CAC GAG CCG TGA TC-3′
Figure W1. Relative mRNA expression levels (white bars) of EGFR, Trio, TNFRSF18, MAPK7, and MAPK8 in OSCCs with expression
profiling results (black bars).
Figure W1. (continued).
Figure W1. (continued).
